Overview

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability and treatment response of paliperidone palmitate administered as once-monthly injections to patients with schizophrenia.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pte Ltd
Treatments:
Paliperidone Palmitate